ZernikeMeta et al. invest €2m in CellPly
ZernikeMeta Ventures (ZMV), the Atlante Seed fund and Italian Angels for Growth (IAG) have invested more than €2m in CellPly, an Italian molecular diagnostics start-up.
ZMV invested via its €14m Ingenium Emilia Romagna II Fund. Atlante Seed is a €10m Intesa Sanpaolo Group fund managed by IMI Fondi Chiusi.
The seed funding provided will allow CellPly to further develop its diagnostics platform, which is being developed with the aim of discovering cellular responses to anti-tumour drugs in-vitro, rather than directly in a patient.
According to the company, the global in-vitro diagnostics market was worth around $50bn in 2012.
Company
Founded in 2013 and headquartered in Bologna, CellPly is developing diagnostic tools designed to gauge cellular responses to drug-based treatments towards the treatment of cancer. Its diagnostic platform is meant to measure the efficacy of immunotherapies and chemotherapies on cancer cells.
People
Massimo Bocchi is the CEO of CellPly. Andrea Ballestri is an investment director at Atlante Seed, while Antonio Leone is a partner and director at IAG.
More on Southern Europe
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater
EU FSR could impact PE fundraising with potential rise in ‘clean funds’
FSR could lead GPs to create funds without foreign LPs; red tape around sovereign wealth funds likely
Letter from the editor: Unquote is moving to Mergermarket
Unquote Editor Harriet Matthews outlines Unquote.com's upcoming move to the Mergermarket platform and the new capabilities and intelligence that this brings to Unquote readers
GP Profile: Apheon builds on family roots, mulls exits and reinvestment opportunities
Belgian GP, formerly known as Ergon, to continue to target family- and entrepreneur-owned European businesses
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater